First Experience of Personalized Tissue Engineering In Situ for Thoracic Surgery of the Sarcoma Patient: MSCs-Containing Minimally Manipulated Cells and Individualized Micropore Titanium Sternum in One-Year Follow-Up Case Report
Abstract
Individually customized grafts have become standard for reconstructing extensive chest wall defects resulting from surgical interventions for sternal malignant neoplasms. However, the outcomes of these graft implantations can be further improved by administering patient-derived cells, which have minimal oncological risks. In 2021, a 52-year-old woman with chondrosarcoma (pT2N0M0G2, stage IIB) was admitted to the Department of Thoracic Surgery. The patient presented with a large tumor in the body of the sternum, measuring 81 × 94 × 91 mm, according to the computed tomography (CT) scan. To address this, an individualized endoprosthesis was modeled and created using the original 'pincer-dock' construction based on CT-scan screens. The mononuclear cell fraction (MNCs) was obtained from the patient's peripheral blood one week before surgery using a Haemonetics cell separation device and cryopreserved until the day of the procedure. The resulting 30 mL MNC suspension contained 12 mln cells per 1 mL. We performed flow cytometry analysis using a FACS Aria III flow cytometer to confirm the presence of mesenchymal stromal cells in the MNCs. We also performed immunostaining for S-100, a common tumor marker for benign and malignant diseases, and D2-40, a marker for the lymphatic endothelium that reacts with Kaposi's sarcoma and a subset of angiosarcomas. None of the cells were positive for either marker. Approximately 3 ml of the MNC suspension was injected into each rib edge and 30 ml into the operating field immediately after resection. The titanium endoprosthesis was placed in the sternal defect, and the body of the endoprosthesis was securely covered with a laparoscopically mobilized omental flap. After a one-year follow-up, the patient showed no signs of recurrence or post-surgical complications. These outstanding functional and cosmetic results highlight the potential for the broader clinical utilization of minimally manipulated cells in personalized medicine in oncology. These results could pave the way for wider clinical application of peripheral blood-derived minimally manipulated cells in personalized medicine as an adjuvant for titanium endoprosthesis reconstruction of osteochondral defects in patients with sarcoma.
2. Sandler G, Hayes-Jordan A. Chest wall reconstruction after tumor resection. Semin Pediatr Surg. 2018;27(3):200-206.
3. Dzian A, Živčák J, Penciak R, et al. Implantation of a 3D-printed titanium sternum in a patient with a sternal tumor. World J Surg Oncol. 2018;16(1):7.
4. Chapelier AR, Missana MC, Couturaud B, et al. Sternal resection and reconstruction for primary malignant tumors. Ann Thorac Surg. 2004;77(3):1001-6.
5. Krasilnikova OA, Baranovskii DS, Yakimova AO, et al. Intraoperative Creation of Tissue-Engineered Grafts with Minimally Manipulated Cells: New Concept of Bone Tissue Engineering In Situ. Bioengineering (Basel). 2022;9(11):704.
6. Cao S, Zhao Y, Hu Y, et al. New perspectives: In-situ tissue engineering for bone repair scaffold. Compos B Eng. 2020;202:108445.
7. Baranovskii DS, Klabukov ID, Arguchinskaya NV, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig. 2022;9:7.
8. Marx RE, Harrell DB. Translational research: The CD34+ cell is crucial for large-volume bone regeneration from the milieu of bone marrow progenitor cells in craniomandibular reconstruction. Int J Oral Maxillofac Implants. 2014;29(2):e201-9.
9. Krasilnikova OA, Klabukov ID, Baranovskii DS, et al. The new legal framework for minimally manipulated cells expands the possibilities for cell therapy in Russia. Cytotherapy, 2021;23(8):754-755.
10. Kaigler D, Avila-Ortiz G, Travan S, et al. Bone engineering of maxillary sinus bone deficiencies using enriched CD90+ stem cell therapy: a randomized clinical trial. J Bone Miner Res. 2015;30(7):1206-16.
11. Lyamina S, Baranovskii D, Kozhevnikova E, et al. Mesenchymal Stromal Cells as a Driver of Inflammaging. Int J Mol Sci. 2023;24(7):6372.
12. Lin CS, Ning H, Lin G, et al. Is CD34 truly a negative marker for mesenchymal stromal cells?. Cytotherapy 2012;14(10):1159-63.
13. Yasuhara S, Yasunaga Y, Hisatome T, et al. Efficacy of bone marrow mononuclear cells to promote bone regeneration compared with isolated CD34+ cells from the same volume of aspirate. Artif Organs. 2010;34(7):594-9.
14. Kolobaev I, Baranovskii D, Usachev V, et al. World first implantation of personalized micropore titanium sternum with motile costal clip connections: two-year follow-up case report. Iran J Med Sci. 2024;49(4):268-271.
15. Elahi L, Zellweger M, Abdelnour-Berchtold E, et al. The size and sternal involvement of chest wall resections for malignant disease predict postoperative morbidity. Transl Cancer Res. 2022;11(5):1162-1172.
16. Kachroo P, Pak PS, Sandha HS, et al. Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas. J Thorac Oncol. 2012;7(3):552–8.
17. Kolbenschlag J, Hörner C, Sogorski A, et al. Sternal Reconstruction with the Omental Flap-Acute and Late Complications, Predictors of Mortality, and Quality of Life. J Reconstr Microsurg. 2018;34(5):376–82.
18. Voss B, Bauernschmitt R, Will A, et al. Sternal reconstruction with titanium plates in complicated sternal dehiscence. Eur J Cardiothorac Surg. 2008;34(1):139–45.
19. Carvajal C, Ramirez AM, Guerrero-Macías S, et al. A South American Experience With Postoperative Complications Following Chest Wall Reconstruction for Neoplasms. World J Surg. 2021;45(10):2982–92.
20. Baranovskii DS, Akhmedov BG, Demchenko AG, et al. Minimally Manipulated Bone Marrow-Derived Cells Can Be Used for Tissue Engineering In Situ and Simultaneous Formation of Personalized Tissue Models. Bull Exp Biol Med. 2022;173(1):139-45.
Files | ||
Issue | Vol 19 No 1 (2025) | |
Section | Case Report(s) | |
DOI | https://doi.org/10.18502/ijhoscr.v19i1.17830 | |
Keywords | ||
Endoprosthesis; Minimally manipulated cells; Regenerative medicine; Sarcoma; Stem cell transplantation; Tissue engineering |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |